Skip to main content
Top
Published in: CEN Case Reports 4/2020

01-11-2020 | Multiple Myeloma | Case Report

A case of proliferative glomerulonephritis with immunoglobulin A1-lambda deposits successfully treated by chemotherapy

Authors: Yasuo Kusunoki, Tomoko Namba-Hamano, Tsunayuki Kakimoto, Satoko Yamamoto, Natsuko Ikeda, Keiko Wakabayashi, Kumie Teramoto, Masanobu Takeji

Published in: CEN Case Reports | Issue 4/2020

Login to get access

Abstract

A 74-year-old man presented with nephrotic syndrome and kidney insufficiency. Laboratory tests revealed monoclonal gammopathy of immunoglobulin A-lambda. Renal biopsy revealed diffuse mesangial proliferation and double-contoured basement membranes. Immunofluorescent analyses showed granular deposition of immunoglobulin A and C3 at the capillary walls and mesangial regions. Immunohistochemistry suggested monoclonal deposition of immunoglobulin A1-lambda. Electron microscopic analyses showed finely granular electron-dense deposits at mesangial and subendothelial areas. These findings suggested immunoglobulin A-type proliferative glomerulonephritis with monoclonal immunoglobulin deposits. Based on the results of bone marrow aspiration, multiple myeloma was diagnosed. Because the renal manifestation was considered to be affected by monoclonal gammopathy, chemotherapy was initiated rather than immunomodulatory therapy. Although bortezomib and dexamethasone proved ineffective, second chemotherapy with elotuzumab, lenalidomide, and dexamethasone was successful, and kidney function recovered. Effective treatments for proliferative glomerulonephritis with monoclonal immunoglobulin deposits have not been established. This represents the first description of a patient successfully treated for proliferative glomerulonephritis with monoclonal immunoglobulin deposits by chemotherapy using elotuzumab.
Appendix
Available only for authorised users
Literature
1.
go back to reference Nasr SH, Satoskar A, Markowitz GS, Valeri AM, Appel GB, Stokes MB, et al. Proliferative glomerulonephritis with monoclonal IgG deposits. J Am Soc Nephrol. 2009;20(9):2055–64 (Epub 2009/05/28).CrossRef Nasr SH, Satoskar A, Markowitz GS, Valeri AM, Appel GB, Stokes MB, et al. Proliferative glomerulonephritis with monoclonal IgG deposits. J Am Soc Nephrol. 2009;20(9):2055–64 (Epub 2009/05/28).CrossRef
2.
go back to reference Oe Y, Joh K, Sato M, Taguma Y, Onishi Y, Nakayama K, et al. Proliferative glomerulonephritis with monoclonal IgM-kappa deposits in chronic lymphocytic leukemia/small lymphocytic leukemia: case report and review of the literature. CEN Case Rep. 2013;2(2):222–7 (Epub 2013/11/01).CrossRef Oe Y, Joh K, Sato M, Taguma Y, Onishi Y, Nakayama K, et al. Proliferative glomerulonephritis with monoclonal IgM-kappa deposits in chronic lymphocytic leukemia/small lymphocytic leukemia: case report and review of the literature. CEN Case Rep. 2013;2(2):222–7 (Epub 2013/11/01).CrossRef
3.
go back to reference Vignon M, Cohen C, Faguer S, Noel LH, Guilbeau C, Rabant M, et al. The clinicopathologic characteristics of kidney diseases related to monotypic IgA deposits. Kidney Int. 2017;91(3):720–8 Epub 2017/01/11.CrossRef Vignon M, Cohen C, Faguer S, Noel LH, Guilbeau C, Rabant M, et al. The clinicopathologic characteristics of kidney diseases related to monotypic IgA deposits. Kidney Int. 2017;91(3):720–8 Epub 2017/01/11.CrossRef
4.
go back to reference Nasr SH, Valeri AM, Cornell LD, Fidler ME, Sethi S, D'Agati VD, et al. Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. Clin J Am Soc Nephrol. 2012;7(2):231–9 (Epub 2011/12/14).CrossRef Nasr SH, Valeri AM, Cornell LD, Fidler ME, Sethi S, D'Agati VD, et al. Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. Clin J Am Soc Nephrol. 2012;7(2):231–9 (Epub 2011/12/14).CrossRef
5.
go back to reference Fogo AB, Lusco MA, Najafian B, Alpers CE. AJKD atlas of renal pathology: cryoglobulinemic glomerulonephritis. Am J Kidney Dis. 2016;67(2):e5–7 (Epub 2016/01/24).CrossRef Fogo AB, Lusco MA, Najafian B, Alpers CE. AJKD atlas of renal pathology: cryoglobulinemic glomerulonephritis. Am J Kidney Dis. 2016;67(2):e5–7 (Epub 2016/01/24).CrossRef
6.
go back to reference Fogo AB, Lusco MA, Najafian B, Alpers CE. AJKD atlas of renal pathology: immunotactoid glomerulopathy. Am J Kidney Dis. 2015;66(4):e29–30 (Epub 2015/09/27).CrossRef Fogo AB, Lusco MA, Najafian B, Alpers CE. AJKD atlas of renal pathology: immunotactoid glomerulopathy. Am J Kidney Dis. 2015;66(4):e29–30 (Epub 2015/09/27).CrossRef
7.
go back to reference Nagae H, Tsuchimoto A, Tsuruya K, Kawahara S, Shimomura Y, Noguchi H, et al. Clinicopathological significance of monoclonal IgA deposition in patients with IgA nephropathy. Clin Exp Nephrol. 2017;21(2):266–74 Epub 2016/05/14.CrossRef Nagae H, Tsuchimoto A, Tsuruya K, Kawahara S, Shimomura Y, Noguchi H, et al. Clinicopathological significance of monoclonal IgA deposition in patients with IgA nephropathy. Clin Exp Nephrol. 2017;21(2):266–74 Epub 2016/05/14.CrossRef
8.
go back to reference Suzuki H, Yasutake J, Makita Y, Tanbo Y, Yamasaki K, Sofue T, et al. IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis. Kidney Int. 2018;93(3):700–5 (Epub 2018/01/14).CrossRef Suzuki H, Yasutake J, Makita Y, Tanbo Y, Yamasaki K, Sofue T, et al. IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis. Kidney Int. 2018;93(3):700–5 (Epub 2018/01/14).CrossRef
9.
go back to reference Noto R, Kamiura N, Ono Y, Tabata S, Hara S, Yokoi H, et al. Successful treatment with bortezomib and dexamethasone for proliferative glomerulonephritis with monoclonal IgG deposits in multiple myeloma: a case report. BMC Nephrol. 2017;18(1):127 (Epub 2017/04/08).CrossRef Noto R, Kamiura N, Ono Y, Tabata S, Hara S, Yokoi H, et al. Successful treatment with bortezomib and dexamethasone for proliferative glomerulonephritis with monoclonal IgG deposits in multiple myeloma: a case report. BMC Nephrol. 2017;18(1):127 (Epub 2017/04/08).CrossRef
10.
go back to reference Fancher KM, Bunk EJ. Elotuzumab: the first monoclonal antibody for the treatment of multiple myeloma. J Adv Pract Oncol. 2016;7(5):542–7 (Epub 2016/07/01).PubMed Fancher KM, Bunk EJ. Elotuzumab: the first monoclonal antibody for the treatment of multiple myeloma. J Adv Pract Oncol. 2016;7(5):542–7 (Epub 2016/07/01).PubMed
11.
go back to reference Berdeja J, Jagannath S, Zonder J, Badros A, Kaufman JL, Manges R, et al. Pharmacokinetics and safety of elotuzumab combined with lenalidomide and dexamethasone in patients with multiple myeloma and various levels of renal impairment: results of a phase Ib study. Clin Lymphoma Myeloma Leukemia. 2016;16(3):129–38 (Epub 2016/01/23).CrossRef Berdeja J, Jagannath S, Zonder J, Badros A, Kaufman JL, Manges R, et al. Pharmacokinetics and safety of elotuzumab combined with lenalidomide and dexamethasone in patients with multiple myeloma and various levels of renal impairment: results of a phase Ib study. Clin Lymphoma Myeloma Leukemia. 2016;16(3):129–38 (Epub 2016/01/23).CrossRef
Metadata
Title
A case of proliferative glomerulonephritis with immunoglobulin A1-lambda deposits successfully treated by chemotherapy
Authors
Yasuo Kusunoki
Tomoko Namba-Hamano
Tsunayuki Kakimoto
Satoko Yamamoto
Natsuko Ikeda
Keiko Wakabayashi
Kumie Teramoto
Masanobu Takeji
Publication date
01-11-2020
Publisher
Springer Singapore
Published in
CEN Case Reports / Issue 4/2020
Electronic ISSN: 2192-4449
DOI
https://doi.org/10.1007/s13730-020-00480-y

Other articles of this Issue 4/2020

CEN Case Reports 4/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.